Why the Medical Developments International (ASX:MVP) share price is sinking 8% today
This healthcare share is ending the week deep in the red…
James Mickleboro has been a Motley Fool contributor since late 2015. After studying economics at university back home in the United Kingdom, James came to live in Australia and managed to land a job at an Australian fund manager. This was the start of a love affair with Australian equities and he hasn t looked back since. James is part of the CFA Institute s Chartered Financial Analyst program and hopes it teaches him how to become an astute investor which allows him to help others with their own investing. Outside of reading and researching he spends many a late night watching the English Premier League and Seinfeld reruns.
The green whistle blows for Gordon Naylorâs next move
Save
Share
When CSL acquired flu vaccine business Seqirus from Novartis in 2015, Gordon Naylor was stunned by the lack of financial awareness among employees.
The former CSL chief financial officer and Seqirus boss was charged with merging and transforming two loss-making business units (Seqirus and bioCSL). His aim was for Seqirus to generate $1 billion in revenue within five years and for it to become profitable â something it achieved in 2018.
Gordon Naylor says it is critical for all employees to have at least a basic understanding of a companyâs financial position.Â